Biosimilars Have Driven Down Cost of Infliximab Biosimilars Have Driven Down Cost of Infliximab
Biosimilars have driven down the costs of originator biologics, but it isn ' t clear whether those savings are being passed on to patients or increasing access to the drugs.MDedge News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - February 14, 2024 Category: Gastroenterology Tags: Gastroenterology Source Type: news

Dose Escalation With Infliximab Biosimilar Can Restore Responses in IBD
(MedPage Today) -- LAS VEGAS -- In patients with inflammatory bowel disease who lost response after infliximab (Remicade) induction, escalating the maintenance dose of the subcutaneous infliximab biosimilar CT-P13 improved clinical response and... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - February 3, 2024 Category: Gastroenterology Source Type: news

Switching Twice With Infliximab Biosimilars Not Linked With IBD Flare Risk
(MedPage Today) -- LAS VEGAS -- Biosimilar switching was not tied to flare in patients with inflammatory bowel disease (IBD), according to a retrospective cohort study. Patients who switched from infliximab (Remicade) to an infliximab biosimilar... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - January 29, 2024 Category: Gastroenterology Source Type: news

A New Test Could Save Arthritis Patients Time, Money, and Pain
(MedPage Today) -- SAN DIEGO -- Erinn Maury, MD, knew infliximab (Remicade) wasn't the right drug for Patti Schulte, a rheumatoid arthritis patient the physician saw at her Millersville, Maryland, practice. Schulte's swollen, painful joints hadn... (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - December 23, 2023 Category: Rheumatology Source Type: news

Higher Visceral Adipose Tissue May Need Higher Infliximab Levels for IBD Remission
WEDNESDAY, Nov. 15, 2023 -- Patients with inflammatory bowel disease (IBD) and high visceral adipose tissue (VAT) may have more difficulty achieving higher infliximab levels necessary to achieve remission, according to a study published in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 15, 2023 Category: Pharmaceuticals Source Type: news

FDA Approves Subcutaneous Infliximab for IBD FDA Approves Subcutaneous Infliximab for IBD
The approval provides an alternative administration option for delivering the drug to patients with moderately to severely active ulcerative colitis or Crohn ' s disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 23, 2023 Category: Consumer Health News Tags: Gastroenterology News Alert Source Type: news

FDA Approves Zymfentra (infliximab-dyyb) Subcutaneous Formulation for the Treatment of People With Inflammatory Bowel Disease
JERSEY CITY, N.J.--(BUSINESS WIRE) October 23, 2023 --Today, Celltrion USA announced that the U.S. Food and Drug Administration (FDA) has approved Zymfentra (infliximab-dyyb) for maintenance therapy in adults with moderately to severely active... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 23, 2023 Category: Drugs & Pharmacology Source Type: news

Surprising Link Between Weight Gain and RA Activity
(MedPage Today) -- In patients with rheumatoid arthritis (RA) treated with infliximab (Remicade), increases in body mass index (BMI) scores over time were not associated with increased disease activity or faster radiographic progression. In fact... (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - October 10, 2023 Category: Primary Care Source Type: news

Johnson & Johnson Poised For A Muted Q2?
Johnson & Johnson stock (NYSE: JNJ) will report its Q2 2023 results on Thursday, July 20. We expect the company’s revenues to come in at $24.6 billion, marginally below the consensus estimate of $24.7 billion. This would mark year-over-year growth of about 2%. Earnings will likely come in at about…#johnsonjohnson #jnj #darzalexerleada #remicade #medtech #abiomed #johnsonjohnsons #consumerhealthcare #johnsonjohnsonpeers #peercomparisons (Source: Reuters: Health)
Source: Reuters: Health - July 14, 2023 Category: Consumer Health News Source Type: news

Immunomodulators Flop for COVID-19 Pneumonia Outcomes
(MedPage Today) -- Immunomodulators abatacept (Orencia), cenicriviroc, and infliximab (Remicade) all failed to improve time to recovery for patients hospitalized with COVID-19 pneumonia in the randomized, double-masked ACTIV-1 platform trial.... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - July 12, 2023 Category: Infectious Diseases Source Type: news

How Fat Burden May Affect IBD Drug Dosing How Fat Burden May Affect IBD Drug Dosing
Target levels of infliximab in patients with IBD and high visceral adipose fat burden may be higher, suggesting the potential need to personalize dosing strategies.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - June 3, 2023 Category: Allergy & Immunology Tags: Gastroenterology News Source Type: news

Biologic-to-Biosimilar Switches Deemed Safe and Effective Biologic-to-Biosimilar Switches Deemed Safe and Effective
Triple switching from infliximab biologic to biosimilar for IBD found no new safety or efficacy concerns.MDedge News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - June 2, 2023 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Fewer Discontinuations With Infliximab for UC Maintenance Tx Fewer Discontinuations With Infliximab for UC Maintenance Tx
Researchers compared the rates of discontinuation after 1 year due to lack of efficacy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 9, 2023 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Adalimumab + Methotrexate Beneficial for Pediatric Crohn Disease
THURSDAY, April 27, 2023 -- For pediatric Crohn disease (PCD) patients, treatment with methotrexate combined with adalimumab, but not infliximab, is associated with a reduction in treatment failure, according to a study published online March 31 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 27, 2023 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Reports Q1 2023 Results
New Brunswick, N.J. (April 18, 2023) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2023. “Our first quarter results demonstrate strong performance across all three segments of our business and reflect the dedication of Johnson & Johnson colleagues around the world,” said Joaquin Duato, Chairman of the Board and Chief Executive Officer. “With this momentum, I look forward to the remainder of the year, one filled with exciting catalysts that will create both near- and long-term value for patients and all of our stakeholders.”OVERALL FINANCIAL RESULTSQ1($ in Millions, except EPS)2...
Source: Johnson and Johnson - April 18, 2023 Category: Pharmaceuticals Tags: Financial Source Type: news